Amicus Therapeutics (FOLD) Insider Trading & Ownership $9.61 -0.05 (-0.52%) (As of 08:27 AM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Amicus Therapeutics (NASDAQ:FOLD) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)7Amount OfInsider Selling(Last 12 Months)$4.53 M Get FOLD Insider Trade Alerts Want to know when executives and insiders are buying or selling Amicus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address FOLD Insider Buying and Selling by Quarter Ad Colonial MetalsA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Amicus Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/6/2024Bradley L CampbellCEOSell7,901$12.50$98,762.50 11/1/2024Bradley L CampbellCEOSell7,500$11.46$85,950.00 10/1/2024Bradley L CampbellCEOSell7,500$10.60$79,500.00 9/3/2024Bradley L CampbellCEOSell7,500$11.71$87,825.00 8/1/2024Bradley L CampbellCEOSell7,500$10.34$77,550.00 7/5/2024Bradley L CampbellCEOSell6,100$10.00$61,000.00 Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. 5/1/2024Bradley L CampbellCEOSell7,500$10.07$75,525.00 3/5/2024Margaret G McglynnDirectorSell7,500$13.40$100,500.00 2/15/2024Bradley L CampbellCEOSell4,167$14.00$58,338.00 2/15/2024David Michael ClarkInsiderSell4,427$14.00$61,978.00 2/15/2024John F CrowleyChairmanSell31,614$13.81$436,589.34 2/6/2024Ellen RosenbergInsiderSell400$13.00$5,200.00 1/22/2024John F CrowleyChairmanSell55,327$12.36$683,841.72 1/16/2024John F CrowleyChairmanSell31,614$12.78$404,026.92 1/10/2024John F CrowleyChairmanSell31,614$13.65$431,531.10 1/9/2024David Michael ClarkInsiderSell1,384$14.00$19,376.00 1/8/2024Samantha ProutCAOSell30,767$14.00$430,738.00 1/2/2024Bradley L CampbellCEOSell15,833$14.23$225,303.59 1/2/2024Ellen RosenbergInsiderSell30,000$14.21$426,300.00 12/27/2023Ellen RosenbergInsiderSell5,000$14.07$70,350.00 12/26/2023Samantha ProutCAOSell7,659$14.00$107,226.00 12/19/2023Jeff CastelliInsiderSell17,500$13.25$231,875.00 12/15/2023John F CrowleyChairmanSell6,043$12.66$76,504.38 12/1/2023Bradley L CampbellCEOSell11,702$11.08$129,658.16 12/1/2023John F CrowleyChairmanSell6,043$11.08$66,956.44 (Data available from 1/1/2013 forward) FOLD Insider Trading Activity - Frequently Asked Questions Who is on Amicus Therapeutics's Insider Roster? The list of insiders at Amicus Therapeutics includes Bradley L Campbell, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Jeff Castelli, John F Crowley, Margaret G Mcglynn, Michael Raab, and Samantha Prout. Learn more on insiders at FOLD. What percentage of Amicus Therapeutics stock is owned by insiders? 2.20% of Amicus Therapeutics stock is owned by insiders. Learn more on FOLD's insider holdings. Which Amicus Therapeutics insiders have been selling company stock? The following insiders have sold FOLD shares in the last 24 months: Bradley L Campbell ($2,870,654.46), Daphne Quimi ($62,450.00), David Michael Clark ($538,469.88), Ellen Rosenberg ($925,945.48), Jeff Castelli ($231,875.00), John F Crowley ($6,576,283.60), Margaret G Mcglynn ($295,950.00), Michael Raab ($49,942.64), and Samantha Prout ($1,055,059.09). How much insider selling is happening at Amicus Therapeutics? Insiders have sold a total of 998,935 Amicus Therapeutics shares in the last 24 months for a total of $12,606,630.15 sold. Amicus Therapeutics Key ExecutivesMr. Bradley L. Campbell M.B.A. (Age 48)CEO, President & Director Compensation: $984.09k6 recent tradesMs. Ellen S. Rosenberg (Age 61)Chief Legal Officer & Corporate Secretary Compensation: $733.94kMr. David M. Clark (Age 49)Chief People Officer Compensation: $701.39kDr. Jeffrey P. Castelli (Age 52)Chief Development Officer Compensation: $709.64kMr. Simon Nicolas Reade Harford (Age 64)Chief Financial Officer Ms. Samantha Prout (Age 46)Chief Accounting Officer & Controller Dr. Jill Weimer Ph.D.Chief Science OfficerAndrew FaughnanSenior Director of Investor RelationsMr. Patrik S. Florencio Esq.Global Chief Compliance & Risk OfficerMs. Diana MooreHead of Global Corporate Communications More Insider Trading Tools from MarketBeat Related Companies BHC Insider Trades ARWR Insider Trades PRGO Insider Trades BBIO Insider Trades BHVN Insider Trades ALLK Insider Trades BPMC Insider Trades EXEL Insider Trades EXAS Insider Trades RGEN Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:FOLD) was last updated on 11/25/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
